16-(2-{2-[2-(2-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-hexadecanoicacid 2,5-dioxo-pyrrolidin-1-yl ester | 702701-51-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 16-(2-{2-[2-(2-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-hexadecanoicacid 2,5-dioxo-pyrrolidin-1-yl ester
• 英文别名: (2,5-Dioxopyrrolidin-1-yl) 16-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]hexadecanoate
• CAS: 702701-51-7
• 化学式: C₃₅H₆₅NO₁₂
• 分子量: 691.901
• InChiKey: RPRXLBHGPKXNHT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  48
• 可旋转键数：
  39
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  138
• 氢给体数：
  0
• 氢受体数：
  12

反应信息

• 作为产物：
  描述：

  N-羟基丁二酰亚胺 、 16-[2-[2-[2-[2-[2-[2-(2-Methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]hexadecanoic acid 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以77%的产率得到16-(2-{2-[2-(2-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-hexadecanoicacid 2,5-dioxo-pyrrolidin-1-yl ester
  参考文献：
  名称：

  Bna Conjugates and Methods of Use

  摘要：

  本发明公开了改性利钠肽化合物及其共轭物。具体而言，提供了至少连接有一个修饰基团的hBNP的共轭形式。这些改性利钠肽化合物共轭物保留了刺激cGMP产生、结合NPR-A受体、降低动脉血压以及在某些实施例中相对于未经改性的对应利钠肽化合物具有改善的循环半衰期的活性。这些化合物和共轭物的口服、静脉注射、肠内、皮下、肺部和静脉形式可作为治疗和/或治疗心脏病症，特别是充血性心力衰竭的治疗。还公开了包含具有各种长度和构型的寡聚结构的修饰基团。此外，还公开了hBNP化合物的类似物，其氨基酸序列与天然序列不同。

  公开号：

  US20080207505A1

文献信息

• Natriuretic compounds, conjugates, and uses thereof
  申请人：——

  公开号：US20040203081A1

  公开（公告）日：2004-10-14

  Modified n atriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-A receptor, and in some embodiments an improved half-life in circulation as compared to unmodified counterpart natriuretic compounds. Oral, parenteral, subcutaneous, and intravenous forms of the compounds and conjugates may be prepared as treatments and/or therapies for heart conditions particularly congestive heart failure. Modifying moieties comprising oligomeric structures having a variety of lengths and configurations are also disclosed. Analogs of the n atriuretic compound are also disclosed, having an amino acid sequence that is other than the native sequence.

  本发明公开了经修饰的利尿化合物及其共轭物。特别是，本发明提供了 hBNP 的共轭形式，其中包括至少一个连接在其上的修饰分子。修饰的利钠化合物共轭物保留了刺激 cGMP 生成、与 NPR-A 受体结合的活性，在某些实施方案中，与未修饰的对应利钠化合物相比，其在循环中的半衰期得到了改善。口服、肠外、皮下和静脉注射形式的化合物和共轭物可制备成治疗和/或治疗心脏疾病，特别是充血性心力衰竭的药物。此外，还公开了由具有各种长度和构型的低聚物结构组成的修饰分子。此外，还公开了具有不同于原生序列的氨基酸序列的利尿化合物类似物。
• MODIFIED NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF
  申请人：Nobex Corporation

  公开号：EP1569683A2

  公开（公告）日：2005-09-07
• NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF
  申请人：James Kenneth D.

  公开号：US20100216714A1

  公开（公告）日：2010-08-26

  Modified natriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-A receptor, and in some embodiments an improved half-life in circulation as compared to unmodified counterpart natriuretic compounds. Oral, parenteral, enteral, subcutaneous, pulmonary, and intravenous forms of the compounds and conjugates may be prepared as treatments and/or therapies for heart conditions particularly congestive heart failure. Modifying moieties comprising oligomeric structures having a variety of lengths and configurations are also disclosed. Analogs of the natriuretic compound are also disclosed, having an amino acid sequence that is other than the native sequence.
• US7648962B2
  申请人：——

  公开号：US7648962B2

  公开（公告）日：2010-01-19
• US7662773B2
  申请人：——

  公开号：US7662773B2

  公开（公告）日：2010-02-16